Ongoing VA-administered Phase III study in which intranasal flu vaccine Flumist and flu shot are co-administered in over 2000 patients in 20 VA hospitals hopes to show concurrent protection for the elderly, CEO Fred Kurland said Sept. 28. Highlighting the possible pharmacoeconomic benefit, Kurland said the study aims to replicate results of an NIH study that showed a 60% increase in protection for the combination over the flu shot alone. Aviron plans to use non-traditional marketing methods for Flumist, such as e-commerce, Kurland said. A cytomegalovirus treatment being developed with NIH is currently on clinical hold, but Kurland expects to start clinical trials in early 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth